We are live on ! Find out more
NI

Nextech Invest Portfolio holdings

AUM $1.42B
1-Year Est. Return 304.47%
This Fund
S&P 500
This Quarter Est. Return
+16.93%
1 Year Est. Return
+304.47%
3 Year Est. Return
+631.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$631M
AUM Growth
+$94M
Cap. Flow
+$34.1M
Cap. Flow %
5.41%
Top 10 Hldgs %
94.49%
Holding
13
New
2
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$25.2M
2
RLAY icon
Relay Therapeutics
RLAY
+$24.4M
3
SLN
Silence Therapeutics
SLN
+$20.7M
4
BOLD
Boundless Bio
BOLD
+$17.5M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$11.9M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$44.6M
2
ARVN icon
Arvinas
ARVN
+$12.6M
3
MRSN
Mersana Therapeutics
MRSN
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$38.5B
$203M 32.17%
6,296,740
– –
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.17B
$72.7M 11.52%
5,285,714
+1,000,000
+23% +$11.9M
TYRA icon
3
Tyra Biosciences
TYRA
$1.85B
$66.5M 10.54%
4,055,861
+1,537,279
+61% +$25.2M
CRGX
4
DELISTED
CARGO Therapeutics
CRGX
$59M 9.35%
2,642,502
– –
ARVN icon
5
Arvinas
ARVN
$531M
$58.1M 9.22%
1,408,394
-287,251
-17% -$12.6M
TNGX icon
6
Tango Therapeutics
TNGX
$4.21B
$43.9M 6.97%
5,533,980
– –
RLAY icon
7
Relay Therapeutics
RLAY
$4.01B
$31.9M 5.06%
3,846,409
+2,500,000
+186% +$24.4M
CGEM icon
8
Cullinan Oncology
CGEM
$1.06B
$20.8M 3.3%
1,221,145
– –
SLN
9
Silence Therapeutics
SLN
$546M
$20.6M 3.26%
+952,400
New +$20.7M
SPRY icon
10
ARS Pharmaceuticals
SPRY
$579M
$19.5M 3.09%
1,910,029
– –
BOLD
11
Boundless Bio
BOLD
$55.3M
$17.5M 2.77%
+1,228,069
New +$17.5M
MRSN
12
DELISTED
Mersana Therapeutics
MRSN
$17.3M 2.74%
154,253
-84,880
-35% -$8.44M
AMAM
13
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-3,129,300
Closed -$44.6M

Similar funds

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return
KCMH
Kontiki Capital Management (HK) Hong Kong $1.43B AUM 9.81% 1-Year Est. Return
APCM
Alaska Permanent Capital Management Anchorage, Alaska $1.43B AUM 13.12% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Nextech Invest's Q1 2024 Portfolio in Review

As of Q1 2024, Nextech Invest held 13 positions worth $631M, up 18% from $537M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Nextech Invest deployed $34.1M of net new capital in Q1 2024, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Silence Therapeutics: 952,400 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $12.6M trimmed.

  • Nextech Invest's largest Q1 2024 buy was Silence Therapeutics: 952,400 shares worth $20.6M.
  • Nextech Invest added most to Tyra Biosciences in Q1 2024, an estimated $25.2M increase.
  • Nextech Invest's biggest Q1 2024 reduction was Arvinas, cutting an estimated $12.6M.
  • Nextech Invest fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $44.6M.
  • Nextech Invest's ten largest holdings make up 94% of its $631M portfolio in Q1 2024.
  • Nextech Invest opened 2 new positions and closed 1 in Q1 2024.
  • Nextech Invest's portfolio value rose 18% quarter-over-quarter to $631M.

Based on Nextech Invest's 13F filing for Q1 2024, filed 15 May 2024.